Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omthera Pharmaceuticals Inc.

Division of AstraZeneca PLC
www.omthera.com

Latest From Omthera Pharmaceuticals Inc.

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer

Deal Watch: Shire Increases Rare Disease Holdings, Abbott Expands Latin American Interests

MedImmune and Bristol announce immuno-oncology combination trials with new partners on the same day, while AC Immune and Piramal Imaging will collaborate to develop an Alzheimer’s diagnostic to trace abnormal Tau protein in neuronal tissue.

BioPharmaceutical Deals

2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A

According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.

BioPharmaceutical Business Strategies

AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance

AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Michael Davidson, MD, CMO
  • Contact Info
  • Omthera Pharmaceuticals Inc.
    Phone: (908) 741-4399
    707 State Rd.
    Princeton, NJ 08540
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register